“…(3)), provides the starting point for the structure-based drug design process. [92,93], pyrido[2,3-d]pyrimidines [86,88,[94][95][96][97][98], pyrrolo[2,3-d]pyrimidines [99,100], thieno[2,3-d]pyrimidines [101][102][103], purines [104], furo[2,3-d]pyrimidines [105][106][107], quinazolines [55, 73, 88, 98, 101, Therapeutic options for PCP have been comprehensively reviewed by Queener [69] in 1995 and Fishman [70,71] in 1998. A review by Gangjee et al, focused specifically on antifolates, was published in 1996 [72].…”